講演|18:30~19:00 Considerations for anti VEGF therapy in 2026 <演者> Chui Ming Gemmy Cheung 先生 Professor, Duke-NUS, National University of Singapore Director, Clinical Translational Research, Singapore Eye Research Institute
講演|17:00〜17:40 Evolving Treatment Strategies in nAMD and RVO: Early Disease Control with EYLEA8mg <演者> Prof. Andrew Chang Sydney Eye Hospital, Australia
講演|12:10〜12:40 Clinical efficacy and potential advantage of aflibercept 8mg <演者> Sobha Sivaprasad 先生 Retinal Clinical Studies at the UCL Institute of Ophthalmology in London, UK